Arcus biosciences appoints biotech industry veteran, andrew perlman, m.d., ph.d. and gilead's svp of research biology, michael quigley, ph.d.

Hayward, calif.--(business wire)--arcus biosciences, inc. (nyse:rcus), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that andrew perlman, m.d., ph.d. and michael quigley, ph.d. have joined the company's board of directors. dr. perlman will also serve as a member of arcus's nominating and corporate governance committee. drs. perlman and quigley both have outstanding track records of success working in innovative and intensely comp
RCUS Ratings Summary
RCUS Quant Ranking